Unclassified Cardiomyopathies

Unclassified cardiomyopathies are a heterogeneous group of cardiac disorders that do not fit into the four main categories of cardiomyopathies (dilated, hypertrophic, restrictive, and arrhythmogenic).
These conditions present atypical morphological and functional characteristics and may have genetic, metabolic, or toxic causes.

Depending on the specific type, the main pathophysiological mechanisms include:

• Neurohormonal dysfunction: typical of Takotsubo cardiomyopathy, where an excess of catecholamines induces altered myocardial contractility.
• Genetic alterations: responsible for spongiform and mitochondrial cardiomyopathies, affecting myocardial structure and function.
• Pathological accumulation: metabolic and storage diseases (Fabry disease, hemochromatosis) cause the infiltration of substances into the myocardium, altering its function.
• Toxic factors: certain drugs and toxic substances can induce direct myocardial damage or alter cellular metabolism.

Below is a brief overview of all unclassified cardiomyopathies and their key characteristics.

Takotsubo Cardiomyopathy

Definition and Pathogenesis

Also known as "broken heart syndrome," it is a transient cardiomyopathy often triggered by severe emotional or physical stress. It is characterized by acute left ventricular dysfunction with apical hypokinesia and basal hyperkinesia.

Clinical Presentation

The main symptoms mimic an acute myocardial infarction:

• Chest pain
• Dyspnea
• ECG abnormalities (ST-segment elevation, T-wave inversion)
• Moderate troponin elevation

Diagnosis

Echocardiography and cardiac magnetic resonance imaging (MRI) reveal the characteristic "takotsubo" morphology (resembling a Japanese octopus pot). Coronary angiography excludes significant coronary stenosis.

Treatment

Management is supportive, including beta-blockers and ACE inhibitors. Recovery usually occurs within 4–8 weeks.

Spongiform Cardiomyopathy (LVNC)

Definition and Pathogenesis

Spongiform cardiomyopathy, also known as left ventricular noncompaction (LVNC), is characterized by abnormal myocardial compaction during fetal development, with prominent trabeculations and deep recesses. It is associated with mutations in sarcomeric genes (*MYH7, ACTC1*).

Clinical Presentation

Patients may present with:

• Progressive heart failure
• Ventricular arrhythmias
• Thromboembolic events

Diagnosis

Contrast echocardiography and cardiac MRI allow visualization of hypertrophic trabeculations and intertrabecular recesses.

Treatment

Management includes standard heart failure therapy and anticoagulation in patients at high thrombotic risk.

Mitochondrial Cardiomyopathies

Definition and Pathogenesis

Mitochondrial cardiomyopathies result from mutations in mitochondrial genes that impair cardiac energy production. They can manifest as early-onset heart failure and systemic myopathies.

Clinical Presentation

Patients may present with:

• Chronic fatigue
• Associated skeletal myopathy
• Progressive dilated cardiomyopathy

Diagnosis

Muscle biopsy and genetic testing confirm the diagnosis.

Treatment

There is no specific therapy; management aims to optimize cardiac function with ACE inhibitors and beta-blockers.

Hypereosinophilic Cardiomyopathy

Definition and Pathogenesis

It is caused by eosinophilic infiltration of the myocardium, leading to fibrosis and Loeffler’s endocarditis.

Clinical Presentation

Includes signs of heart failure and systemic thromboembolism.

Diagnosis

Echocardiography reveals endocardial fibrosis, and blood tests show eosinophilia.

Treatment

Corticosteroids and anticoagulants are the mainstay of therapy.

Toxic Cardiomyopathies

Definition and Pathogenesis

These are caused by exposure to cardiotoxic drugs (e.g., anthracyclines, cocaine, alcohol), leading to direct myocardial damage.

Clinical Presentation

Patients present with symptoms of heart failure and arrhythmias.

Diagnosis

Cardiac MRI shows areas of myocardial fibrosis.

Treatment

Discontinuation of the toxic agent and standard heart failure therapy.

Idiopathic Restrictive Cardiomyopathy

Definition and Pathogenesis

A rare form of cardiomyopathy characterized by abnormal myocardial stiffness without an identifiable cause (such as infiltrates or storage diseases). Ventricular filling is impaired, leading to diastolic heart failure.

Clinical Presentation

Symptoms are related to venous congestion:

• Dyspnea on exertion and at rest
• Peripheral edema
• Fatigue
• Atrial arrhythmias (e.g., atrial fibrillation)

Diagnosis

• Echocardiography: non-dilated ventricles with reduced compliance.
• Cardiac catheterization: elevated filling pressures.
• Cardiac MRI: rules out infiltrative diseases (e.g., amyloidosis, sarcoidosis).

Treatment

There is no specific therapy. Diuretics help reduce congestion, and rhythm control medications may be used. In advanced cases, heart transplantation may be considered.

Endomyocardial Fibrotic Cardiomyopathy

Definition and Pathogenesis

This rare disorder is characterized by progressive endomyocardial fibrosis, leading to ventricular filling restriction and intracavitary thrombosis.

Clinical Presentation

• Signs of right heart failure
• Systemic embolisms
• Exercise intolerance

Diagnosis

Echocardiography reveals thickened endocardial fibrotic tissue and thrombi. Cardiac MRI can confirm the diagnosis.

Treatment

Therapy includes anticoagulants, diuretics, and, in selected cases, surgical resection of the fibrotic tissue.

Danon Disease

Definition and Pathogenesis

Danon disease is an X-linked lysosomal storage disorder caused by mutations in the LAMP2 gene. It leads to severe hypertrophic cardiomyopathy with progressive dysfunction.

Clinical Presentation

• Hypertrophic cardiomyopathy with progressive heart failure
• Associated skeletal myopathy
• Ventricular arrhythmias and conduction blocks
• Cognitive impairment (in more severe cases)

Diagnosis

• Cardiac biopsy: shows evidence of lysosomal accumulation.
• Genetic testing: identifies the LAMP2 mutation.

Treatment

Heart transplantation may be necessary in advanced cases. Treatment is mainly supportive for heart failure and arrhythmias.

Cardiomyopathies Associated with Neuromuscular Disorders

Definition and Pathogenesis

Certain neuromuscular disorders, such as **Duchenne and Becker muscular dystrophies**, cause progressive cardiomyopathies due to dystrophin deficiency, leading to myocardial degeneration.

Clinical Presentation

• Progressive heart failure
• Ventricular arrhythmias
• Reduced exercise capacity

Diagnosis

Echocardiography and cardiac MRI reveal progressive ventricular dilation and fibrosis.

Treatment

Management includes beta-blockers, ACE inhibitors, and implantable defibrillators for patients at risk of malignant arrhythmias.

Cardiomyopathies Due to Autoimmune Diseases

Definition and Pathogenesis

Autoimmune diseases such as **systemic sclerosis, systemic lupus erythematosus, and inflammatory myopathies** can affect the myocardium, causing chronic inflammation and fibrosis.

Clinical Presentation

• Dyspnea and fatigue
• Arrhythmias and conduction blocks
• Associated pericarditis

Diagnosis

• Echocardiography: thickening of the myocardium and impaired contractility.
• Cardiac MRI: evidence of fibrosis.
• Autoantibodies: ANA, anti-SSA, anti-Scl-70.

Treatment

Corticosteroids and immunosuppressants can improve cardiac function. Standard heart failure management is applied for symptomatic control.

Bibliography

Bibliography
1. Maron BJ et al. Contemporary Definitions and Classification of Cardiomyopathies. Circulation. 2006;113(14):1807-1816.
2. Elliott P et al. Classification of Cardiomyopathies: A Position Statement. Eur Heart J. 2008;29(2):270-276.
3. Finsterer J. Primary Myopathies and the Heart. Scand Cardiovasc J. 2008;42(1):9-24.
4. Lyon AR et al. Takotsubo Syndrome: Aetiology, Presentation and Treatment. Heart. 2016;102(18):1461-1469.
5. Oechslin EN, Jenni R. Left Ventricular Non-Compaction Revisited. Eur Heart J. 2011;32(12):1446-1456.
6. Kühl U et al. Viral Persistence in Myocardium and Progressive Dysfunction. Circulation. 2005;112(13):1965-1970.
7. Ghadri JR et al. Long-Term Prognosis of Takotsubo Syndrome. J Am Coll Cardiol. 2018;72(8):874-882.
8. Packer M et al. Neurohormonal Antagonism in Heart Failure. Circulation. 1999;100(5):549-557.
9. Basso C et al. Arrhythmogenic Cardiomyopathy: A Disease of Cardiac Stem Cells? Circulation. 2012;125(4):635-648.
10. Pinto YM et al. Revised Definition of Dilated Cardiomyopathy. Eur Heart J. 2016;37(23):1850-1858.